The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InHarvest Portfolios Group Inc. reduced its stake in Johnson & Johnson by 4.4% during the fourth quarter of 2025, offloading 15,389 shares to bring its total holding to 333,145 shares. Despite this portfolio rebalancing, Johnson & Johnson raised its quarterly dividend to $1.34 per share and maintains a Moderate Buy consensus rating. Institutional ownership remains robust at 69.55%, bolstered by increased positions from major investment firms.
This adjustment occurs as healthcare stocks show mixed performance, with peer companies like Pfizer and Merck maintaining steady levels per market data. The increased involvement of institutional giants such as Vanguard and Wellington Management underscores continued confidence in the company's cash flows, particularly following a recent earnings beat. The dividend hike serves as a positive signal for income-focused investors amidst broader market volatility.
Looking ahead, traders are monitoring JNJ price levels following the latest quarterly close. Market participants are focused on upcoming catalysts, including the U.S. Producer Price Index (PPI) data on May 13, 2026, which could impact defensive sectors. Additionally, speeches by Fed officials Collins and Kashkari in mid-May will be scrutinized for clues on interest rate paths and their subsequent effect on high-yield value stocks.